SPC Logo

Pabrinex Intravenous High Potency Injection

Last Updated on eMC 29-Jun-2016 View changes  | Kyowa Kirin Ltd Contact details

1. Name of the medicinal product

Pabrinex Intravenous High Potency, Solution for injection

2. Qualitative and quantitative composition

Each presentation (carton) contains either 5ml or 10ml ampoules. Each pair of ampoules to be used in treatment is labelled Pabrinex No 1 and Pabrinex No 2.

Each No 1 ampoule contains:

5ml ampoule

10ml ampoule

Thiamine Hydrochloride

250mg

500mg

Riboflavin (as Phosphate Sodium)

4mg

8mg

Pyridoxine Hydrochloride

50mg

100mg

Each No 2 ampoule contains:

5ml ampoule

10ml ampoule

Ascorbic Acid

500mg

1000mg

Nicotinamide

160mg

320mg

Anhydrous Glucose

1000mg

2000mg

Excipients with known effect:

This medicinal product contains approximately 3.4 mmol (or 79mg) sodium per dose (1 pair of 5ml ampoules). To be taken into consideration by patients on a controlled sodium diet.

This medicinal product contains approximately 6.8 mmol (or 158mg) sodium per dose (1 pair of 10ml ampoules). To be taken into consideration by patients on a controlled sodium diet.

For the full list of excipients, see section 6.1.

3. Pharmaceutical form

Solution for injection

4. Clinical particulars
4.1 Therapeutic indications

Pabrinex is indicated in adults and children for rapid therapy of severe depletion or malabsorption of the water soluble vitamins B and C:

• particularly in alcoholism, where a severe depletion of thiamine can lead to Wernicke's encephalopathy

• after acute infections

• post-operatively

• in psychiatric states

Also used to maintain levels of vitamin B and C in patients on chronic intermittent haemodialysis.

4.2 Posology and method of administration

Pabrinex is also available as an Intramuscular High Potency Injection. Therefore before administration, ensure that both the Summary of Product Characteristics and ampoule labels refer to the INTRAVENOUS injection.

Adults and elderly:

Rapid therapy of severe depletion or malabsorption of the water soluble vitamins B and C, particularly in alcoholism, where a severe depletion of thiamine can lead to Wernicke's encephalopathy

10ml solution from Ampoule Number 1

PLUS

10ml solution from Ampoule Number 2

OR

15ml solution from Ampoule Number 1

PLUS

15ml solution from Ampoule Number 2

2 to 3 pairs of 5ml ampoules* (1 pair = ampoule 1 + ampoule 2) diluted with 50ml to 100ml infusion solution (physiological saline or glucose 5%) and administered over 30 minutes every 8 hours, or at the discretion of the physician.

* or equivalent volume of 5ml and/or 10ml ampoules

Psychosis following narcosis or E.C.T; toxicity from acute infections

5ml Ampoule Number 1

PLUS

5ml Ampoule Number 2

10ml of the mixed ampoules diluted with 50ml to 100ml infusion solution (physiological saline or glucose 5%) administered over 30 minutes twice daily for up to 7 days.

Haemodialysis

5ml Ampoule Number 1

PLUS

5ml Ampoule Number 2

10ml of the mixed ampoules diluted with 50ml to 100ml infusion solution (physiological saline or glucose 5%) administered over 30 minutes once every two weeks at the end of dialysis.

Paediatric population

Pabrinex Intravenous High Potency, Solution for Injection is rarely indicated for administration to children; however, suitable doses are as follows:

Under 6 years

6 - 10 years

10 - 14 years

14 years and over

quarter of the adult dose

third of the adult dose

half to two thirds of the adult dose

as for the adult dose

Method of administration

Pabrinex Intravenous High Potency, Solution for Injection should be administered by drip infusion. Equal volumes of the contents of ampoules number 1 and 2 should be added to 50ml to 100ml physiological saline or 5% glucose and infused over 30 minutes (see sections 6.3 and 6.6).

4.3 Contraindications

Hypersensitivity to the active substances or to any of the excipients listed in section 6.1.

4.4 Special warnings and precautions for use

Although potentially serious allergic adverse reactions such as anaphylactic shock may occur rarely during, or shortly after, parenteral administration of Pabrinex, such rare occurrence of serious allergic reactions should not preclude the use of Pabrinex in patients who need treatment by this route of administration particularly those at risk of Wernicke's encephalopathy - for whom treatment with parenteral thiamine is essential.

Initial warning signs of a reaction to Pabrinex are sneezing or mild asthma and those treating patients need to note that the administration of further injections to such patients may give rise to anaphylactic shock. Facilities for treating anaphylactic reactions should be available whenever Pabrinex Intravenous High Potency is administered. To minimise the risk of such events with Pabrinex Intravenous High Potency, this medicinal product should be administered by infusion over a period of 30 minutes.

This medicine is for injection into a vein only and should not be given by any other route

Care should be taken to ensure that the route of administration used (intramuscular or intravenous) is that intended – reports of unintentional administration by the wrong route have been received; these incidents have not been associated with serious adverse reactions.

In common with all parenteral products each ampoule should be visually inspected prior to administration and should not be used if particulates are present.

4.5 Interaction with other medicinal products and other forms of interaction

The content of pyridoxine may interfere with the effects of concurrent levodopa therapy.

4.6 Fertility, pregnancy and lactation

No adverse effects have been reported at recommended doses when used as clinically indicated.

Animal studies are insufficient with respect to reproductive toxicity (see section 5.3). The potential risk for humans is unknown.

Caution should be exercised when prescribing to pregnant women.

4.7 Effects on ability to drive and use machines

No studies on the effects on the ability to drive and use machines have been performed. However given the nature of the product, no effects are anticipated.

4.8 Undesirable effects

Adverse reactions reported as possibly associated to Pabrinex are presented in the following table by MedDRA System Organ Class (SOC), Preferred Term and frequency. The following frequency categories are used:

Very common (>1/10);

Common (>1/100, <1/10);

Uncommon (>1/1,000, <1/100);

Rare (>1/10,000, <1/1,000);

Very rare (<1/10,000), including isolated reports.

Post-marketing adverse reactions are reported voluntarily from a population with an unknown rate of exposure. Therefore it is not possible to estimate the true incidence of adverse reactions and the frequency is “unknown”.

Tabulated summary of adverse reactions

SYSTEM ORGAN CLASS (SOC)

FREQUENCY

ADVERSE REACTION

Immune system disorders

Unknown

Hypersensitivity (including anaphylaxis, rash and urticaria)

Nervous system disorders

Unknown

Paraesthesia

Vascular disorders

Unknown

Hypotension

General disorders and administration site conditions

Unknown

Injection site reactions (including pain and swelling)

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard.

4.9 Overdose

In the unlikely event of overdosage, treatment is symptomatic and supportive.

5. Pharmacological properties
5.1 Pharmacodynamic properties

Pabrinex Intravenous High Potency contains vitamins B1, B2, B6, nicotinamide, vitamin C and glucose.

ATC code: A11EB

5.2 Pharmacokinetic properties

Not supplied.

5.3 Preclinical safety data

There are no pre-clinical data of relevance to the prescriber which are additional to that already included in other sections of the Summary of Product Characteristics.

6. Pharmaceutical particulars
6.1 List of excipients

Edetic acid

Sodium hydroxide

Water for Injections

6.2 Incompatibilities

This medicinal product must not be mixed with other medicinal products except those mentioned in section 6.6.

If it is necessary to administer Pabrinex Intravenous High Potency in infusion, it is recommended that Pabrinex IV HP is administered in physiological saline or glucose 5%.

6.3 Shelf life

Before opening:

24 months.

After opening:

Chemical and physical in-use stability of intravenous high potency vitamins B and C has been demonstrated in the following intravenous infusion fluids for the number of hours stated in the table below, at room temperature:

Intravenous infusion fluid

In the light

Glucose 5%

7 hours

Physiological saline (sodium chloride 0.9%)

7 hours

Glucose 4.3% with sodium chloride 0.18%

4 hours

Glucose 5% with potassium chloride 0.3%

4 hours

Sodium lactate M/6

7 hours

Although no further specific data are available, the solutions are expected to be stable for longer periods when protected from light.

From a microbiological point of view, the product should be used immediately. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 24 hours at 2 to 8°C, unless dilution has taken place in controlled and validated aseptic conditions.

The diluted solutions should not be frozen.

6.4 Special precautions for storage

Do not store above 25°C. Keep the container in the outer carton. Do not freeze.

For storage conditions after dilution of the medicinal product, see section 6.3.

6.5 Nature and contents of container

Pabrinex Intravenous High Potency, Solution for Injection is supplied in pairs of amber glass ampoules of 5ml or 10ml. Packs contain either, six or ten pairs of 5ml ampoules, or five pairs of 10ml ampoules.

Not all pack sizes may be marketed.

6.6 Special precautions for disposal and other handling

Compatibility of intravenous high potency vitamins B and C has been demonstrated with the following infusion fluids:

• Glucose 5%

• Physiological saline (sodium chloride 0.9%)

• Glucose 4.3% with sodium chloride 0.18%

• Glucose 5% with potassium chloride 0.3%

• Sodium lactate M/6

Please refer to section 6.3 for details regarding storage following dilution in each of these fluids.

Any unused medicinal product or waste material should be disposed of in accordance with local requirements.

7. Marketing authorisation holder

Archimedes Pharma UK Limited

Galabank Business Park

Galashiels

TD1 1QH

United Kingdom

8. Marketing authorisation number(s)

PL 12406/0003

9. Date of first authorisation/renewal of the authorisation

Date of first authorisation: October 1993

Date of the latest renewal: October 2003

10. Date of revision of the text

May 2016

Company contact details

Kyowa Kirin Ltd

Company image
Address

Galabank Business Park, Galashiels, TD1 1QH

Medical Information e-mail
Medical Information Direct Line

+ 44 (0)1896 664 000

Before you contact this company: often several companies will market medicines with the same active ingredient. Please check that this is the correct company before contacting them. Why?

Active ingredients

ascorbic acid, glucose, anhydrous, nicotinamide, pyridoxine, riboflavin, thiamine

Legal categories

POM - Prescription Only Medicine

This site uses cookies. By continuing to browse the site you are agreeing to our policy on the use of cookies. Continue